 | | Vol. 11.41 – 18 October, 2023 |
| |
|
|
| Investigators found that lymphopenia was a prominent characteristic of immune perturbation in COVID-19 patients with encephalopathy, especially those with acute necrotizing encephalopathy.
[Signal Transduction And Targeted Therapy] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| In vitro, adolescent peripheral blood mononuclear cells produce more cytokines, priming A549 cells for stronger interferon responses to SARS-CoV-2.
[EMBO Reports] |
|
|
|
| Researchers examined the small extracellular vesicle lipid profile of plasma of recovered COVID-19 patients (RCs). Their study may offer new insights into the mechanism of organ dysfunction and help identify novel therapeutic targets in the RCs.
[Scientific Reports] |
|
|
|
| Investigators performed extensive immune phenotyping using flow cytometry. Moreover, to compare the range of values observed in the co-infected case, they included a larger number of mono-infected cases with SARS-CoV-2.
[Allergy, Asthma & CLinical Immunology] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Scientists demonstrated that human-induced pluripotent stem cell-derived skin organoids were susceptible to Mpox virus infection and support infectious virus production.
[Nature Microbiology] |
|
|
|
| Intravenous Bacille Calmette–Guérin-elicited robust airway T cell influx and elevated plasma and airway antibody titers in both simian immunodeficiency virus-infected and naive animals.
[Nature Microbiology] |
|
|
|
| Researchers showed that a llama-derived nanobody M4 neutralized multiple GII.4 variants with high potency in human intestinal enteroids.
[Nature Communications] |
|
|
|
| Reesearchers investigated how treatment timing affected intestinal memory B-cell and plasmablast repertoires of HIV-1-infected humans.
[Nature Communications] |
|
|
|
| Investigators tested ex vivo viral inhibitory activity of T cell responses induced by a multivalent HIV vaccine based on the replication-incompetent recombinant adenovirus serotype 26 vectors with a mosaic immunogen strategy, designed for broad immune coverage of diverse HIV-1 strains.
[Journal Of Virology] |
|
|
|
|
| Scientists highlight the tuberculosis vaccines that are in the development pipeline and review the basis for optimism in both the clinical and preclinical space. They describe immune signatures that could act as immunological correlates of protection to facilitate the development and comparison of vaccines.
[NPJ Vaccines] |
|
|
|
| The authors review the evolutionary trajectories and processes that underpin the emergence of these lineages and identify the most prevalent sublineages. They discuss the potential origins of second-generation BA.2 lineages.
[Nature Microbiology] |
|
|
|
|
| ContraFect, Corp. announced that the US FDA completed the safety review of its Investigational New Drug (IND) application for CF-370 for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, and concluded the company may proceed with its Phase I clinical study.
[ContraFect, Corp.] |
|
|
|
|
| November 16 – 18, 2023
Boston, Massachusetts, United States |
|
|
|
|
|
| | King’s College London – Harrow, England, United Kingdom |
|
|
|
| | Harvard Medical School – Boston, Massachusetts, United States |
|
|
|
| | Medical College of Wisconsin – Milwaukee, Wisconsin, United States |
|
|
|
| | University of Washington – Medical Lake, Washington, United States |
|
|
|
| | Massachusetts General Hospital – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
